How Are Precancerous Cells Removed?

Precancerous cells are removed through a range of procedures tailored to where in the body they appear and how advanced the changes are. In the cervix, a thin heated wire loop can shave away abnormal tissue in minutes. In the esophagus, radiofrequency energy can destroy an entire sheet of damaged lining. On the skin, a prescription cream applied at home can trigger the immune system to clear the problem without any cutting at all. The specific technique matters because each organ has its own anatomy, its own risks, and its own track record for keeping those cells from coming back.

Cervical Precancer Removal

The cervix is probably where most people first encounter the idea of precancerous cells, usually after an abnormal Pap smear or a positive HPV test. The two most common removal procedures are loop electrosurgical excision (LEEP) and cold-knife conization (CKC). LEEP uses a thin, electrically charged wire loop to cut out a cone-shaped piece of cervical tissue containing the abnormal cells. CKC does essentially the same thing with a surgical scalpel under anesthesia, and it tends to remove a deeper cone of tissue.

For most patients, outcomes between the two are comparable. Meta-analyses show no significant differences in recurrence rates, rates of residual disease, or secondary bleeding between LEEP and CKC.¹ CKC does cut deeper, which can be relevant for certain types of precancer like adenocarcinoma in situ. But because LEEP achieves similar cancer-prevention results with fewer complications during pregnancy afterward, it tends to be preferred for people who want to preserve fertility.²

Cryotherapy is a third option, especially in lower-resource settings, where a probe cooled with liquid nitrogen or carbon dioxide freezes and destroys the abnormal tissue. Recurrence rates about a year after cryotherapy or LEEP sit around 5%, while CKC comes in lower at roughly 1.4%.³ The trade-off is that CKC carries a higher rate of complications, including a greater risk of premature delivery in later pregnancies. All three methods are well-established, and the choice usually depends on the severity of the precancer, the depth of tissue that needs to come out, and the patient’s reproductive plans.

Skin Precancers

Actinic keratoses, the rough, scaly patches that develop on sun-exposed skin, are among the most common precancerous lesions. They’re also among the most treatable. Many people are surprised that some skin precancers can be cleared with a cream rather than a scalpel.

Topical fluorouracil (often called 5-FU) is a chemotherapy drug applied directly to the skin. It works by interfering with DNA replication in rapidly dividing abnormal cells while leaving normal skin largely intact. It is considered extremely effective for treating widespread actinic keratoses, and repeated courses can delay the development of significant precancerous and cancerous skin lesions indefinitely.⁴ A typical course lasts several weeks, during which the treated skin becomes red, crusty, and uncomfortable before healing. That temporary ugliness is actually the point: it signals the drug is targeting the abnormal cells.

Imiquimod works differently. Rather than poisoning cells directly, it activates the local immune system. When applied to the skin, it triggers immune cells to recognize and attack abnormal tissue. It is approved for actinic keratoses, superficial basal cell carcinoma, and anogenital warts.⁵ Research has shown it is effective and safe for a range of cutaneous precancers and early cancers.⁶

Beyond creams, dermatologists also use liquid nitrogen cryotherapy (a quick freeze applied directly to individual spots), curettage (scraping the lesion off), and photodynamic therapy, which uses a light-sensitizing chemical painted on the skin followed by exposure to a specific wavelength of light that destroys the treated cells. The choice depends largely on how many lesions there are and where they sit. A single spot on the hand might get frozen in seconds during a routine office visit; a forehead covered in dozens of keratoses is better suited to a field-treatment approach like fluorouracil or photodynamic therapy that treats an entire area at once.

Precancers in the Digestive Tract

Polyps in the colon and rectum are one of the most familiar examples of precancerous growths, and their removal during colonoscopy is the main reason colorectal cancer screening works as well as it does. The standard technique for flat or sessile polyps is endoscopic mucosal resection (EMR), in which the doctor injects fluid beneath the polyp to lift it away from the deeper layers of the bowel wall, then uses a wire snare to cut it free.⁷ EMR is the standard treatment for colorectal adenomas and early cancers that have not spread to nearby lymph nodes.⁸

For larger or more complex lesions, endoscopic submucosal dissection (ESD) allows the entire growth to be peeled away in a single piece. ESD is more technically demanding and takes longer, but it provides a complete specimen the pathologist can examine for clean margins, which means fewer questions about whether anything was left behind. Both methods avoid major surgery for the vast majority of patients who would otherwise face a bowel resection.⁹

Barrett’s Esophagus and Radiofrequency Ablation

Barrett’s esophagus is a condition in which chronic acid reflux replaces the normal esophageal lining with a type of tissue that does not belong there. Over time, that abnormal lining can develop precancerous changes called dysplasia. Radiofrequency ablation (RFA) has become the go-to treatment for eliminating dysplastic Barrett’s tissue. A balloon-mounted electrode or a flat paddle is passed down the throat through an endoscope and delivers controlled heat energy across the surface of the abnormal lining, destroying it so normal tissue can regrow.

The evidence for RFA in Barrett’s is strong. In a landmark randomized trial, complete eradication of dysplasia occurred in about 90% of patients with low-grade changes and 81% of those with high-grade changes, compared with roughly 20% in the control groups who underwent sham procedures. Patients who received ablation also had substantially less disease progression and fewer cancers developing afterward.¹⁰ Side effects were manageable: some chest pain and, in a small percentage, narrowing of the esophagus that could be treated with dilation.

Expert centers have continued to refine the approach, and referral-center data confirm that the vast majority of patients can achieve complete clearance of dysplasia with RFA-based protocols.¹¹ For esophageal precancers, cryotherapy offers an alternative. It works on the same freeze-thaw principle used for cervical and skin precancers: rapid cooling followed by thawing causes both direct cell damage and disruption of the blood supply to the abnormal tissue.¹² Cryotherapy tends to be reserved for patients who have not responded fully to RFA or who have anatomic features that make RFA technically difficult.

Breast Precancer and the Margin Question

Ductal carcinoma in situ (DCIS) is the most common breast precancer. The abnormal cells are confined to the milk ducts and have not invaded surrounding tissue, but without treatment a meaningful fraction will progress to invasive cancer. The standard removal approach is lumpectomy, sometimes called breast-conserving surgery, in which the surgeon takes out the area of DCIS along with a rim of normal tissue.

How wide that rim of normal tissue needs to be has been one of the more contentious questions in breast surgery. For years, guidelines suggested aiming for margins of at least 2 mm for DCIS treated with radiation. Practice at major centers has shown that when lumpectomy is followed by radiation therapy, even patients with margins narrower than 2 mm can achieve 10-year local recurrence rates below 5%.¹³ A large national database analysis reinforced this finding, showing no significant difference in recurrence risk between narrow margins and wider margins for most patients, with one exception: women under 50 did show a higher recurrence risk with very narrow margins.¹⁴

Still, when tumor cells are found right at the cut edge (“ink on tumor”), residual disease rates are high, around 88% in one study that examined the surrounding cavity tissue after lumpectomy.¹⁵ The practical takeaway is that some clear margin is needed, but the exact width matters less than whether the surgical team uses a careful, multidisciplinary approach to assess what was removed.

Oral and Head-and-Neck Precancers

Leukoplakia, the white patches that can form inside the mouth, sometimes harbors precancerous changes. Laser surgery has become a preferred tool for removing these lesions. Carbon dioxide lasers vaporize tissue with precision, and because the wound is sealed as the laser cuts, bleeding is minimal and healing is usually fast. Laser resection generally avoids the need for reconstructive surgery and produces minimal scarring, which translates to better function for eating and speaking.¹⁶

Photodynamic therapy (PDT) is another option, especially when precancerous changes are widespread across the mouth or throat. A light-sensitive drug is administered, and then a specific wavelength of light is directed at the tissue. The drug absorbs the light and generates reactive oxygen molecules that destroy the abnormal cells. The method has shown the ability to clear precancerous oral lesions with a complete response in the treated areas.¹⁷ Its advantage over surgery is that it can treat broad areas of tissue without physically cutting, which makes it useful when precancerous changes affect a large region that would be difficult to excise surgically.

Why Removal Is Not Always the End of the Story

One concept that catches people off guard is field cancerization. The idea is that when one spot develops precancerous changes, the surrounding tissue that looks perfectly normal under ordinary examination may already carry genetic damage that sets the stage for new precancers to form. These genetically altered fields can be surprisingly large, up to 7 centimeters across in the head and neck, and they are invisible to the surgeon.¹⁸ This is the main reason that removing a single precancerous lesion does not always prevent cancer: the remaining field can give rise to a new one.

Field cancerization explains why follow-up surveillance matters so much after any precancer removal. It also explains the appeal of “field-directed” treatments, like topical fluorouracil for skin or photodynamic therapy for the mouth, which treat an entire region rather than a single spot. If the field harbors hidden damage, treating the whole area gives you a better shot at clearing it.

Even with surgical excision, the question of whether the edges of the removed tissue are truly free of abnormal cells is critical. Traditional pathology involves slicing the specimen and examining it under a microscope, but molecular margin analysis goes further: it looks for genetic, epigenetic, or protein-level changes in the tissue at the border that standard examination might miss.¹⁹ This kind of analysis is still mostly a research tool, but it points toward a future where surgeons can be more confident that they have gotten everything.

Image-Guided Tools for Seeing What the Eye Cannot

One of the persistent challenges in removing precancerous tissue is knowing exactly where to cut. Abnormal cells can extend beyond what looks suspicious to the naked eye. Fluorescence visualization is one approach to this problem. In the mouth, for example, tissue is illuminated with a specific light source, and areas with abnormal biology lose their natural fluorescence, showing up as dark patches against the surrounding healthy glow. This allows surgeons to map out disease that would otherwise be missed.²⁰

Autofluorescence has shown promise as a tool for setting surgical margins, though its accuracy has limits. It works best for superficial, well-differentiated lesions and is less reliable when the precancer extends deeper into the tissue or is poorly differentiated.²¹ Think of it as a helpful guide rather than a definitive map. For the moment, it supplements rather than replaces the surgeon’s judgment and the pathologist’s microscope.

The Body’s Own Precancer Surveillance

Your immune system is already in the business of finding and dealing with precancerous cells before any procedure happens. In oral tissue, researchers have documented that immune cells called Langerhans cells and T cells accumulate in areas where precancerous changes are occurring. These immune cells are found in significantly higher numbers in tissue with dysplasia compared with normal tissue, and their concentration increases even further in frank cancer, suggesting an ongoing immune response against the abnormal cells.²² This natural surveillance does not always succeed, which is why procedures exist, but it is the reason many precancerous changes never progress at all.

That understanding has fueled interest in boosting the immune system’s response rather than relying solely on physical removal. Therapeutic vaccines for HPV-related cervical precancers represent perhaps the most advanced version of this idea. Unlike preventive vaccines, which stop initial HPV infection, therapeutic vaccines aim to train the immune system to clear an infection and precancerous lesion that is already there. Clinical trials of DNA-based vaccines like VGX-3100 have demonstrated strong immune activation and viral clearance rates as high as 78% among responders with cervical precancer.²³ None of these vaccines have reached routine clinical use yet, but multiple candidates are in advanced trials.

Chemoprevention and Emerging Approaches

Chemoprevention takes a different angle entirely. Instead of removing precancerous cells after they form, it uses drugs or natural compounds to prevent them from developing in the first place, or to slow their progression once they appear. The concept spans everything from daily aspirin use in certain populations to experimental topical drugs. Chemopreventive agents work through varied mechanisms: some block cancer-causing agents from damaging DNA, some support the DNA repair system, and some slow the cell cycle in cells that already carry damage.²⁴

On the experimental frontier, researchers have developed a topical MEK inhibitor called NFX-179 designed to suppress a key growth-signaling pathway in skin cells. In animal models, applying this gel to sun-damaged skin reduced the formation of new squamous cell cancers by about 60%.²⁵ The drug is designed to break down quickly once it enters the bloodstream, so its effects stay local to the skin. If it proves effective in humans, it could become a complement to existing field-directed treatments for people at high risk of recurring skin precancers.

Another emerging concept involves senescent cells. When cells accumulate enough damage that they stop dividing, they do not always quietly die. Some linger and secrete signals that can actually promote the growth of nearby precancerous cells. In mouse models of pancreatic precancer, using drugs called senolytics to eliminate these lingering senescent cells dramatically reduced the development and progression of precancerous lesions.²⁶ This is early-stage research with no approved human application yet, but it represents a genuinely new way of thinking about precancer management: rather than targeting the abnormal cells themselves, you target the dysfunctional neighbors that help them thrive.